{"id":"W4323044887","doi":"10.1002/jvc2.100","title":"Efficacy of dupilumab in moderate and severe atopic dermatitis","year":2023,"lang":"en","type":"article","venue":"JEADV Clinical Practice","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"LEO Pharma; Galderma; Incyte; Mitsubishi Tanabe Pharma Corporation; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Sanofi; Valeant Pharmaceuticals International; Pfizer; Kyowa Hakko Kirin; Eli Lilly and Company","keywords":"Dupilumab; Atopic dermatitis; Medicine; Placebo; Concomitant; Eczema Area and Severity Index; Internal medicine; Severity of illness; SCORAD; Randomized controlled trial; Dermatology; Gastroenterology; Dermatology Life Quality Index; Pathology; Disease","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001832823,0.0003896098,0.001156045,0.0002710923,0.0001902056,0.0004470659,0.0002269823,0.0003453941,0.001345859],"category_scores_gemma":[0.001491222,0.0001381612,0.000928028,0.0001999656,0.0002346957,0.0002648207,0.0002039834,0.0005713756,0.0001014392],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002612755,"about_ca_system_score_gemma":0.0002762506,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003764923,"about_ca_topic_score_gemma":0.0009959746,"domain_scores_codex":[0.9989666,0.0006280243,0.000117721,0.0001096654,0.0001020209,0.00007589653],"domain_scores_gemma":[0.9986267,0.0006350802,0.0003954793,0.0000388328,0.00006532585,0.0002385515],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.489047,0.004332922,0.1775307,0.006912009,0.008494699,0.0005304359,0.0002598323,0.001425952,0.02750578,0.0005103203,0.002742674,0.2807077],"study_design_scores_gemma":[0.07700718,0.2135523,0.6788667,0.0007738798,0.006745527,0.003102984,0.0002914532,0.002459905,0.007431294,0.0005963854,0.009099443,0.00007293233],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9574346,0.03966793,0.0002257111,0.0001728722,0.00006904709,0.0001635718,0.0003629133,0.00002160815,0.001881695],"genre_scores_gemma":[0.9981083,0.001291582,0.0001473711,0.0001112267,0.00005517225,0.0000438842,0.0001285682,0.000001151345,0.000112822],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001832823,"threshold_uncertainty_score":0.009693027,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05785822509584972,"score_gpt":0.4206879285004587,"score_spread":0.362829703404609,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}